Atosiban Impurity 11 is a related peptide variant formed during atosiban synthesis or degradation. Changes in residue architecture affect chromatographic mobility and folding. Researchers use it to validate analytical resolution and impurity thresholds. Applications include QC development, process monitoring, and degradation-pathway research.
CAT No: Z10-101-170
Synonyms/Alias:Atosiban impurity 11,Mpr-DTyr(Et)-Ile-Thr-Asn-Cys-Pro-Orn-Gly-ol(Mpr1Cys6 bridge)
Atosiban impurity 11 is a synthetic peptide derivative structurally related to the oxytocin antagonist atosiban, commonly encountered as a process-related impurity or degradation product during the manufacture and analysis of peptide-based pharmaceuticals. As a defined impurity, it offers significant value for analytical method development, quality control, and characterization studies in the context of peptide synthesis and pharmaceutical research. The compound's structural and functional resemblance to its parent molecule, along with its unique peptide sequence modifications, enables researchers to investigate critical aspects of peptide stability, process optimization, and impurity profiling within complex peptide drug formulations.
Analytical reference standard: Atosiban impurity 11 is frequently employed as a reference standard in high-performance liquid chromatography (HPLC), mass spectrometry, and related analytical techniques. Its use is essential for the accurate identification, quantification, and separation of related substances within peptide pharmaceutical preparations. By providing a well-characterized benchmark, it enables laboratories to validate analytical methods, monitor impurity levels, and ensure the specificity and sensitivity of detection protocols for pharmaceutical quality assurance.
Impurity profiling and characterization: The presence of this peptide impurity is highly relevant to comprehensive impurity profiling studies, which are critical for understanding the purity and safety of peptide-based drug substances. Researchers utilize atosiban impurity 11 to elucidate degradation pathways, assess the impact of manufacturing conditions, and evaluate the chemical stability of the parent compound under various stress scenarios. Its inclusion in forced degradation and stability studies supports the identification of potential risks and informs process improvements to minimize impurity formation.
Peptide synthesis process optimization: The appearance of specific process-related impurities, such as atosiban impurity 11, provides valuable feedback on the efficiency and selectivity of peptide synthesis protocols. By monitoring its formation during solid-phase or solution-phase peptide synthesis, chemists can refine coupling strategies, optimize protecting group schemes, and adjust purification workflows. This targeted approach helps reduce impurity loads, improve overall yield, and enhance the reproducibility of peptide manufacturing processes.
Structure-activity relationship studies: The structural similarity yet distinct modifications found in atosiban impurity 11 make it a useful tool for probing structure-activity relationships within the oxytocin antagonist class. Researchers can compare its binding affinity, receptor selectivity, and biological stability to those of the parent compound, thereby gaining deeper insight into the molecular determinants of activity and selectivity. Such comparative studies inform rational design of next-generation peptide therapeutics and support the development of more robust drug candidates.
Peptide degradation mechanism elucidation: Investigation of the formation and behavior of atosiban impurity 11 aids in understanding the chemical and enzymatic degradation mechanisms affecting peptide drugs. By isolating and characterizing this impurity under controlled laboratory conditions, scientists can identify susceptible peptide bonds, evaluate the influence of formulation excipients, and predict long-term stability profiles. This knowledge is crucial for developing effective stabilization strategies and ensuring the integrity of peptide pharmaceuticals throughout their lifecycle.
4. Myotropic activity of allatostatins in tenebrionid beetles
5. An Open-label, Single-center, Safety and Efficacy Study of Eyelash Polygrowth Factor Serum
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More